糖皮质激素性骨质疏松症:2019简明临床综述
糖皮质激素广泛用于多种疾病,长期使用最严重的常见不良事件是骨折。糖皮质激素性骨质疏松症(GIOP)呈时间和剂量依赖性发展,即使低剂量,治疗第一个月内即可观察到脆性骨折风险增加。GIOP由多种病理生理机制介导,导致骨形成抑制和骨吸收增加。DXA可能低估接受糖皮质激素治疗患者的骨折风险,多国组织已制定骨折风险评估和治疗指南,推荐抗骨吸收药物和骨形成药物,口服双膦酸盐通常为多数患者的一线治疗。
要点
- 长期糖皮质激素使用最严重的常见不良事件是骨折,GIOP呈时间和剂量依赖性发展。
- 即使低剂量糖皮质激素,治疗第一个月内即可观察到脆性骨折风险增加。
- 口服双膦酸盐通常为多数GIOP患者的一线治疗,骨折风险较高者应更早考虑特立帕肽。
核心结论
- GIOP仍是一个主要的公共卫生问题,用当前和未来潜在的治疗选择至少可部分预防。
研究设计与样本
- 本文为2019年简明临床综述,未报告系统检索范围。
主要发现
- GIOP呈时间和剂量依赖性发展,即使低剂量,治疗第一个月内即可观察到脆性骨折风险增加。
- GIOP由多种病理生理机制介导,导致骨形成抑制和骨吸收增加。
- DXA可能低估接受糖皮质激素治疗患者的骨折风险。
- 与阿仑膦酸钠相比,特立帕肽能显著减少椎体骨折。
关键数值与推荐
- 口服双膦酸盐因疗效确切、安全性好和成本低,通常为多数GIOP患者的一线治疗。
- 对于骨折风险较高的患者,基于特立帕肽与阿仑膦酸钠相比能显著减少椎体骨折,应更早考虑特立帕肽。
- 多国组织制定的指南推荐抗骨吸收药物和骨形成药物,主要基于其改善骨密度的疗效。
临床怎么用
- 多数GIOP患者通常以口服双膦酸盐为一线治疗。
- 骨折风险较高的患者应更早考虑特立帕肽。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucocorticoids remain widely used for many medical conditions, and fractures are the most serious common adverse event related to long-term glucocorticoid use. Glucocorticoid-induced osteoporosis (GIOP) develops in a time- and dose-dependent manner, but even at low doses, an increased risk of fragility fracture may be observed even within the first month of treatment. GIOP is mediated by multiple pathophysiologic mechanisms resulting in an inhibition of bone formation and an increase in bone resorption. The clinical assessment of GIOP has potential pitfalls since dual-energy X-ray absorptiometry (DXA) may underestimate the risk of fracture in patients treated with glucocorticoids. Many national organizations have developed guidelines for assessing fracture risk and treating patients with, or at risk for, GIOP. These groups advocate both antiresorptive agents and bone-forming agents based predominately on their efficacy in improving bone mineral density. Oral bisphosphonates are generally the first-line therapy for GIOP in most patients due to their proven efficacy, good safety, and low cost. For those patients at greater risk of fracture, teriparatide should be considered earlier, based on its ability to significantly reduce vertebral fractures when compared with alendronate. GIOP remains a major public health concern that is at least partially preventable with current and potential future therapeutic options.
引用
- Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019. PMID: 30805679. doi:10.1007/s00198-019-04906-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。